Prescribing Safety Indicators In Patients With Chronic Kidney Disease: A Systematic Review by Smith, Fiona et al.
                          Smith, F., Hole, B., Hayward, S., Caskey, F., Kimpton, G., Sluman, C., &
Whiting, P. (2019). Prescribing Safety Indicators In Patients With Chronic
Kidney Disease: A Systematic Review. Poster session presented at UK
Kidney Week 2019, Brighton, United Kingdom.
Peer reviewed version
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Prescribing Safety Indicators in Patients with 
Chronic Kidney Disease: A Systematic Review 
Smith F 1,2, Hayward S 1,2, Hole B 1,2,  Kimpton G 1,2, Sluman C 1, Whiting P 2, Caskey F 1,2
Author affiliations: 1. North Bristol NHS Trust. 2. University of Bristol.
Corresponding author: fiona.smith@nbt.nhs.uk
Introduction
People with chronic kidney disease (CKD) have high levels of co-morbidity and
polypharmacy which increase their risk of developing drug related problems.
A systematic review published in 2014 (1) collated indicators of prescribing
safety in the general adult population. Whilst all prescribing safety indicators
(PSIs) may be relevant to people with CKD, the number and nature of PSIs
relevant only to people with CKD has not been studied in detail.
Objectives
To perform an updated systematic review, collating PSIs of importance to
people with CKD from the published literature to make the first step in
generating a CKD-focussed PSI library.
Methods
PSIs were defined as statements describing a prescribing event that puts a
patient at risk of potential harm, with emphasis placed on prescribing safety
for adults (age >18) with CKD.
Two systematic processes were used to identify PSIs:
1. General literature search:
The latest systematic review looking at PSIs in the general outpatient
population (1) was used to inform an updated search strategy that
involved accessing the primary literature found in this index review and
replicating the search strategy to find PSIs published up to 2018.
2. CKD specific literature search:
A second systematic strategy looking for CKD specific PSIs by including
terms relating to CKD with no data limits.
Every statement where a prescribing recommendation was made was
extracted from the main text, abstract or tables of the publications.
Each PSI was screened by one of three specialist assessors (two renal
physicians and a senior renal pharmacist). Indicators were graded as being
relevant to the general population (G), relevant only to people with CKD/end
stage kidney disease (C), or relevant to the general population, with special
relevance to individuals with CKD (S). Additionally, PSIs were categorised in
terms of whether the potential harm was direct (D) or through omission (O).
Examples of PSIs are demonstrated in Table 1.
Discussion
This study has systematically identified indicators of prescribing safety and shown that over one third of PSIs are only relevant in people with impaired renal
function. By identifying PSIs more applicable to individuals with CKD it highlights the importance of renal function to prescribing safety.
Further work is being conducted to subcategorise the CKD specific PSIs based on drug class with the aim to create a defined list of PSIs relevant to the CKD
population. This list can be used alone, or alongside general population PSIs, to assess prescribing quality within a population of interest and forms a foundation
step in the development of tools to assess prescribing safety within the CKD population.
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Identifier Explanation Example PSI
GO PSI relevant to general population with potential harm
as a result of omission
Patient with mild-moderate COPD should be
prescribed regular inhaled 2 agonist
CD PSI relevant only to people with CKD or end stage
renal failure with potential harm being a direct effect
For allopurinol prescription in patients with
renal dysfunction doses should be: <200
mg/day if Cr-Cl 20-60 ml/min, 100 mg/day if
CrCl <20ml/min
SO PSI relevant to general population but with special
relevance in CKD patients and potential harm a result
of omission
Patients aged >65 years old should receive
influenza and pneumococcal vaccination
Results
Table 1: Examples of extracted PSIs







Figure 2: PSI grading
PSI Grading
PSIs were graded into various categories:
• C = relevant only to people with CKD (998 PSIs, 35.8%)
• S = relevant to general population, with special relevance to
individuals with CKD (902 PSIs, 32.4%)
• G = relevant to general population (887 PSIs, 31.8%)
Potential Harm
2622 (94.1%) indicators resulted in direct harm and in 165 (5.9%) indicators harm was
secondary to omission.
From PSIs distinctive to patients with CKD (C), 963 (96.5%) resulted in direct harm and
omission resulted in harm in 35 (3.5%).
Potential Harm Direct Omission
All PSIs 94.1 5.9
CKD specific PSIs 96.5 3.5
Table 2: Percentage of PSIs categorised as causing potential harm
